In a recent clinical trial, researchers found that a reduced-dose chemoradiotherapy regimen for early-stage anal cancer may be comparable to standard treatment in achieving short-term tumor response, while causing fewer serious side effects.
May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.
A large cohort study found neoadjuvant radiotherapy improved survival for rectal cancer patients but significantly increased the risk of permanent diverting stomas—especially in upper rectal tumors.
A long-term clinical trial found that structured exercise after colon cancer treatment improved survival outcomes and reduced recurrence rates, offering evidence to support physical activity as part of survivorship care.
Researchers analyzed over 92,000 colonoscopies and proposed a new quality metric—case-mix adjusted polyp count—that outperformed traditional benchmarks in tracking detection performance.
The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.